LONDON (Alliance News) - ANGLE PLC on Friday said its liquid biopsy system Parsortix gained traction at the European Association for Cancer Research Biennial Meeting held in Manchester earlier this month.
The medtech company noted that the performance of the Parsortix system was referenced in two keynote presentations by independent investigators, Caroline Dive of Cancer Research UK Manchester Institute and Klaus Pantel of University Medical Centre Hamburg-Eppendorf.
In additional, three poster presentations for Parsortix were accepted for presentation at the conference, which ANGLE said add to the growing published evidence in support of the use of the system for the harvest of cancer cells from the blood of patients.
"These presentations further highlight that Parsortix is extremely flexible and versatile and that its use is building. At EACR, one of the leading European cancer conferences, we have seen customers develop completely novel potential applications for Parsortix. As well as demonstration of use in additional cancer types and the potential for patient drug response to be assessed. In summary, these presentations further highlight the potential market opportunity and key role Parsortix has to play in the fast growing, liquid biopsy space, a rapidly growing market segment for cancer diagnosis and management," said Founder and Chief Executive Andrew Newland in a statement.
Shares in ANGLE were up 5.1% at 66.75 pence Friday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Angle (AGL)